which reduced the yield of by-product 2-alkoxy-6-cyclohex-
ylmethoxypurine, but only gave ca. 60% 1f under conditions
where the use of TFE gave > 90% yield. Aprotic solvents and
mixtures of aprotic and protic solvents generally gave sig-
nificantly reduced yields of 1f, with the exception of acetonitrile
which gave comparable yields but with by-products.
Notes and references
‡
Typical procedures:
To a suspension of 6-cyclohexylmethoxy-2-fluoro-9H-purine (0.41 g,
1.64 mmol) and sulfanilamide (0.55 g, 3.19 mmol) in trifluoroethanol (4
cm3) was added trifluoroacetic acid (0.61 cm3, 8 mmol). The resulting
solution was boiled under reflux for 16 h, when LC-MS analysis showed
complete conversion of 6-cyclohexylmethoxy-2-fluoro-9H-purine to 1f.
The solvent was removed and the residue was taken up in methanol. The
methanolic solution was filtered through a bed of basic alumina. The filtrate
was concentrated and the residual solid was recrystallised from propan-2-ol
to afford compound 1f as an analytically pure white solid (69%).
To a suspension of 6-amino-2-n-butylsulfonyl-4-cyclohexylmethoxypyr-
imidine 4 (0.20 g, 0.61 mmol) and 4-aminobenzamide (0.17 g, 1.22 mmol)
in trifluoroethanol (4 cm3) was added trifluoroacetic acid (0.24 cm3, 3.05
mmol). The resulting solution was boiled under reflux for 2 h. The solvent
was removed and the solid was extracted into ethyl acetate and washed with
water. The organic layer was collected, dried (Na2SO4) and filtered. The
solvent was removed to yield a white solid. Recrystallisation from MeOH
yielded 2a as a white solid (0.13 g, 0.38 mmol, 62%).
We also found that Amberlyst 15 (polymer-supported
sulfonic acid), camphorsulfonic, hydrochloric, chloroacetic and
formic acid were not useful catalysts at comparable concentra-
tions to TFA. This suggests that for optimal catalysis the acid
strength should be sufficient to generate a viable concentration
of protonated 3 (Scheme 1), but not so strong that the amine
reaction partner is almost completely protonated. When benzy-
lamine was used as nucleophile with 3 in trifluoroethanol or
dimethyl sulfoxide, the formation of product 5b occurred
readily in the absence of TFA. However, addition of 5 mole
equiv. TFA to this reaction dramatically suppressed the
formation of 5b (none detectable after heating at reflux for 1
hour, under which conditions formation of 5b was nearly
quantitative in the absence of the acid). In this case, addition of
TFA clearly completely protonates and deactivates the more
basic benzylamine.
All new compounds gave spectroscopic data and elemental analyses in
accord with their assigned structure.
Similar results were obtained for the substrate 6-amino-2-n-
butylsulfonyl-4-cyclohexylmethoxypyrimidine
410
and
1 (a) B. C. Uff, in Comprehensive Heterocyclic Chemistry, ed. A. J.
Boulton and A. McKillop, Pergamon Press, Oxford, 1984, vol. 2, p. 360;
(b) B. C. Uff, in Comprehensive Heterocyclic Chemistry, ed. A. J.
Boulton and A. McKillop, Pergamon Press, Oxford, 1984, vol. 5, p.
561.
2 H. E. Mertel, in The Chemistry of Heterocyclic Compounds, ed. A
Weissburger, Interscience, New York, 1962, Pt. 2, p. 352.
3 E. Y. Sutcliffe and R. K. Robins, J. Org. Chem., 1963, 28, 1662.
4 G. B. Barlin and N. B. Chapman, J. Chem. Soc., 1965, 3017.
5 C. Enguehard, H. Allouchi, A. Gueiffier and S. L. Buchwald, J. Org.
Chem., 2003, 68, 4367 and references cited therein.
6 S. Ding, N. S. Gray, X. Wu, Q. Ding and P. G. Schultz, J. Am. Chem.
Soc., 2002, 124, 1594.
7 M. Knockaert, P. Greengard and L. Meijer, Trends Pharmacol. Sci.,
2002, 23, 417; Y.-T. Chang, N. S. Gray, G. R. Rosania, D. P. Sutherlin,
S. Kwon, T. C. Norman, R. Sarohia, M. Leost, L. Meijer and P. G.
Schultz, Chem. Biol., 1999, 6, 361.
8 I. R. Hardcastle, R. J. Griffin and B. T. Golding, Ann. Rev. Pharm.
Toxicol., 2002, 42, 325; C. Arris, F. T. Boyle, A. H. Calvert, N. J. Curtin,
P. Jewsbury, J. A. Endicott, A. E. Gibson, B. T. Golding, R. J Griffin,
L. N. Johnson, A. Laurie, N. K. Lembicz, D. R. Newell, M. E. M. Noble,
E. Sausville and R. Schultz, J. Med. Chem., 2000, 43, 2797–2804.
9 T. G. Davies, J. Bentley, C. E. Arris, F. T. Boyle, N. J. Curtin, J. A.
Endicott, A. E. Gibson, B. T. Golding, R. J. Griffin, I. R. Hardcastle, P.
Jewsbury, L. N. Johnson, V. Mesguiche, D. R. Newell, M. E. M. Noble,
J. A. Tucker, L. Wang and H. J. Whitfield, Nat. Struct. Biol., 2002, 9,
745.
2-amino-6-chloropurine, showing that the leaving groups n-
butylsulfonyl and chloride are also compatible with the TFE–
TFA milieu. Thus, heating compound 4 (0.15 M in TFE) at
reflux for 2 hours with 2 mole equiv. 4-aminobenzamide in the
presence of 5 mole equiv. TFA gave 4-(6-amino-4-cyclohex-
ylmethoxypyrimidin-2-ylamino)benzamide 2a (62% isolated
yield of recrystallised, analytically pure material). In a similar
manner, 4 with the appropriate aniline gave the corresponding
adduct 2b–g (yields of analytically pure product in the range
45–71%). 2-Amino-6-chloropurine in TFE did not react with
sulfanilamide in the absence of TFA, but on addition of 5 mole
equiv. of the acid, 77% of 2-amino-6-(4-sulfamoylanilino)-9H-
purine 6 was obtained after heating at reflux for 3 hours.
The reaction conditions described should be suitable for a
variety of nucleophilic substitutions in heterocyclic systems,
especially for weakly nucleophilic amines and for leaving
groups that require effective solvation in order to decay to
product from the tetrahedral intermediate. We have used this
methodology to prepare numerous purines and pyrimidines
related to structures 1 and 2 from a variety of mono- and di-
substituted anilines (cf. ref. 10). With strongly nucleophilic
amines (e.g. benzylamines), addition of TFA is detrimental
because the amine is fully protonated and therefore deacti-
vated.
10 K. L. Sayle, J. Bentley, F. T. Boyle, A. H. Calvert, Y. Cheng, N. J.
Curtin, J. A. Endicott, B. T. Golding, I. R. Hardcastle, P. Jewsbury, V.
Mesguiche, D. R. Newell, M. E. M. Noble, R. J. Parsons, D. J. Pratt, L.
Z. Wang and R. J. Griffin, Bioorg. Med. Chem. Lett., 2003, 13, 3079.
We thank Cancer Research UK (studentship to HJW),
BBSRC (AH), EPSRC (KLS), MRC and AstraZeneca Pharma-
ceuticals for support of this research.
CHEM. COMMUN., 2003, 2802–2803
2803